Group 1 - UTime's Hong Kong subsidiary, UTime Technology, has signed a procurement agreement worth nearly $10 million with Tumu Vertex for smart health devices [1] - The agreement includes an initial purchase order for 50,000 smart health devices, consisting of 25,000 units each of the UT-168 BT Blood Pressure Watch, UR08 ECG Smart Ring, UT-368 4G Blood Pressure Watch, and UR01 Smart Ring [1] - The first batch of products is scheduled for delivery in the first quarter of 2026, with joint quality control procedures established by both parties [1] Group 2 - UTime's CEO highlighted that this cooperation marks a significant strategic breakthrough in the North American market [1] - The order from Tumu Vertex reflects market recognition of UTime's technological capabilities and opens opportunities in the North American medical-grade wearable market [1] - UTime aims to leverage this opportunity to accelerate the development and implementation of next-generation health monitoring technologies [1]

Core Insights - UTime Limited has achieved a significant commercial breakthrough by signing a nearly $10 million procurement agreement with Tumu Vertex LLC for smart health devices, marking a strategic entry into the North American medical-grade wearable market [1][2][3] Group 1: Agreement Details - The signed Sales Agreement includes an initial purchase order for 50,000 premium smart health devices, specifically 25,000 units of the UT-168 BT Blood Pressure Watch, 25,000 units of the UR08 ECG Smart Ring, 25,000 units of the UT-368 4G Blood Pressure Watch, and 25,000 units of the UR01 Smart Ring [2][7] - The agreement adheres to internationally recognized trade frameworks, including FOB Hong Kong delivery, phased payments, and standardized quality assurance systems [2] Group 2: Strategic Importance - This collaboration is viewed as a significant strategic breakthrough for UTime in the North American market, demonstrating market recognition of its technological capabilities [3] - The partnership is expected to accelerate the development and implementation of next-generation health monitoring technologies within UTime's product portfolio [3] Group 3: Market Outlook - UTime anticipates explosive growth in the smart health device market due to increasing global health awareness and longer life expectancies [4] - The major purchase order is expected to strengthen UTime's position in the consumer electronics sector while laying a foundation for strategic growth in the medical technology field [4] Group 4: Company Overview - UTime Limited, trading under the NASDAQ ticker WTO, is engaged in the design, development, production, sales, and brand operation of mobile devices and smart wearable technology globally [5]